-
PCRX Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Pacira BioSciences (PCRX)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 245.97 mm | 245.97 mm | 245.97 mm | 245.97 mm | 245.97 mm | 245.97 mm |
Cash burn (monthly) | 362.67 k | (no burn) | 46.51 mm | 4.63 mm | (no burn) | (no burn) |
Cash used (since last report) | 1.73 mm | n/a | 222.36 mm | 22.15 mm | n/a | n/a |
Cash remaining | 244.23 mm | n/a | 23.60 mm | 223.82 mm | n/a | n/a |
Runway (months of cash) | 673.4 | n/a | 0.5 | 48.3 | n/a | n/a |
13F holders | Current |
---|---|
Total holders | 233 |
Opened positions | 37 |
Closed positions | 45 |
Increased positions | 76 |
Reduced positions | 79 |
13F shares | Current |
---|---|
Total value | 916.46 bn |
Total shares | 49.97 mm |
Total puts | 100.50 k |
Total calls | 1.03 mm |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 7.71 mm | $145.25 bn |
Vanguard | 5.26 mm | $99.17 bn |
Pacer Advisors | 3.26 mm | $61.47 bn |
D. E. Shaw & Co. | 2.26 mm | $42.53 bn |
Renaissance Technologies | 1.99 mm | $37.54 bn |
STT State Street | 1.97 mm | $37.03 bn |
Dimensional Fund Advisors | 1.83 mm | $34.52 bn |
Doma Perpetual Capital Management | 1.75 mm | $32.93 bn |
Millennium Management | 1.49 mm | $27.99 bn |
UBS UBS | 1.37 mm | $25.90 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Feb 25 | Brendan Teehan | Stock Option Common Stock | Grant | Acquire A | No | No | 26.59 | 99,500 | 2.65 mm | 99,500 |
1 Feb 25 | Brendan Teehan | Common Stock | Grant | Acquire A | No | No | 0 | 54,000 | 0.00 | 54,000 |
1 Feb 25 | Riker Lauren Bullaro | Common Stock | Grant | Acquire A | No | No | 0 | 30,600 | 0.00 | 68,516.335 |
1 Feb 25 | Jonathan Slonin | Common Stock | Grant | Acquire A | No | No | 0 | 93,600 | 0.00 | 187,043.511 |
1 Feb 25 | Williams Kristen Marie | Common Stock | Grant | Acquire A | No | No | 0 | 79,200 | 0.00 | 182,112 |
1 Feb 25 | Frank D. Lee | Common Stock | Grant | Acquire A | No | No | 0 | 350,000 | 0.00 | 448,409 |